{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:26:19Z","timestamp":1790857579489,"version":"4.1.0"},"reference-count":198,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["82073582"],"award-info":[{"award-number":["82073582"]}]},{"name":"National Natural Science Foundation of China","award":["82103876"],"award-info":[{"award-number":["82103876"]}]},{"name":"National Natural Science Foundation of China","award":["2023A1515140169"],"award-info":[{"award-number":["2023A1515140169"]}]},{"name":"National Natural Science Foundation of China","award":["2020KTSCX048"],"award-info":[{"award-number":["2020KTSCX048"]}]},{"name":"National Natural Science Foundation of China","award":["2025-001"],"award-info":[{"award-number":["2025-001"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["82073582"],"award-info":[{"award-number":["82073582"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["82103876"],"award-info":[{"award-number":["82103876"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2023A1515140169"],"award-info":[{"award-number":["2023A1515140169"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2020KTSCX048"],"award-info":[{"award-number":["2020KTSCX048"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2025-001"],"award-info":[{"award-number":["2025-001"]}]},{"name":"Guangdong Provincial University Key Platform Featured Innovation Project","award":["82073582"],"award-info":[{"award-number":["82073582"]}]},{"name":"Guangdong Provincial University Key Platform Featured Innovation Project","award":["82103876"],"award-info":[{"award-number":["82103876"]}]},{"name":"Guangdong Provincial University Key Platform Featured Innovation Project","award":["2023A1515140169"],"award-info":[{"award-number":["2023A1515140169"]}]},{"name":"Guangdong Provincial University Key Platform Featured Innovation Project","award":["2020KTSCX048"],"award-info":[{"award-number":["2020KTSCX048"]}]},{"name":"Guangdong Provincial University Key Platform Featured Innovation Project","award":["2025-001"],"award-info":[{"award-number":["2025-001"]}]},{"name":"Fund of Key Laboratory on Leukemia of Jiangxi Provincial Health Commission","award":["82073582"],"award-info":[{"award-number":["82073582"]}]},{"name":"Fund of Key Laboratory on Leukemia of Jiangxi Provincial Health Commission","award":["82103876"],"award-info":[{"award-number":["82103876"]}]},{"name":"Fund of Key Laboratory on Leukemia of Jiangxi Provincial Health Commission","award":["2023A1515140169"],"award-info":[{"award-number":["2023A1515140169"]}]},{"name":"Fund of Key Laboratory on Leukemia of Jiangxi Provincial Health Commission","award":["2020KTSCX048"],"award-info":[{"award-number":["2020KTSCX048"]}]},{"name":"Fund of Key Laboratory on Leukemia of Jiangxi Provincial Health Commission","award":["2025-001"],"award-info":[{"award-number":["2025-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Malignant hematologic diseases, also referred to as hematologic tumors, encompass a series of malignant proliferative disorders of the lymphopoietic system, including leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms. The dysregulation of inflammatory factors or chronic inflammatory responses plays an indispensable role in the onset and progression of these tumors. The C-X-C motif chemokine receptor (CXCR) serves as a key mediator of immune-inflammatory responses. Through its specific regulatory mechanisms, CXCR is involved in the transduction and activation of various signaling pathways, thereby mediating the malignant biological characteristics of blood tumor cells, such as uncontrolled proliferation, differentiation, invasion, migration, autophagy, and apoptosis. In the bone marrow microenvironment, CXCR plays a pivotal role. This review systematically analyzes and elucidates the roles and mechanisms of the CXCR family in hematologic malignancies, aiming to provide new insights into the biological mechanisms and clinical significance of these diseases. The CXCR family holds great potential as a molecular marker for both fundamental research and the clinical diagnosis and treatment of hematologic malignancies.<\/jats:p>","DOI":"10.3390\/biom15050716","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T11:31:49Z","timestamp":1747135909000},"page":"716","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-0456","authenticated-orcid":false,"given":"Yanquan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Dongguan Affiliated Hospital of Guangdong Medical University, The First School of Clinical Medicine, Guangdong Medical University, Dongguan 523808, China"},{"name":"Key Laboratory on Leukemia of Jiangxi Provincial Health Commission, Department of Hematology, The Affiliated Ganzhou Hospital of Nanchang University (Ganzhou People\u2019s Hospital), Ganzhou 341000, China"},{"name":"National Key Laboratory of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-2103","authenticated-orcid":false,"given":"Huanwen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan 523808, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: A voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/112_2020_35","article-title":"CXC chemokine receptors in the tumor microenvironment and an update of antagonist development","volume":"178","author":"Xun","year":"2020","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"ref_3","first-page":"732","article-title":"Correlation between CXCR1 and malignant tumors","volume":"47","author":"Liu","year":"2020","journal-title":"J. Int. Oncology."},{"key":"ref_4","first-page":"853","article-title":"The correlation between CXC chemokine receptor family and malignant tumor","volume":"43","author":"Liu","year":"2022","journal-title":"J. Hebei Med. University."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mollica Poeta, V., Massara, M., Capucetti, A., and Bonecchi, R. (2019). Chemokines and chemokine receptors: New targets for cancer immunotherapy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00379"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/17460441.2016.1233176","article-title":"Drug design strategies focusing on the CXCR4\/CXCR7\/CXCL12 pathway in leukemia and lymphoma","volume":"11","author":"Barbieri","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chirillo, R., Aversa, I., Di Vito, A., Salatino, A., Battaglia, A.M., Sacco, A., Di Sanzo, M.A., Faniello, M.C., Quaresima, B., and Palmieri, C. (2020). FtH-Mediated ROS Dysregulation Promotes CXCL12\/CXCR4 Axis Activation and EMT-Like Trans-Differentiation in Erythroleukemia K562 Cells. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00698"},{"key":"ref_8","first-page":"312","article-title":"Peptides and small molecules blocking the CXCR4\/CXCL12 axis overcome bone marrow-induced chemoresistance in acute leukemias","volume":"41","author":"Pillozzi","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1182\/blood-2015-01-621631","article-title":"IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML Stem cells","volume":"125","author":"Schinke","year":"2015","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2040620720958586","DOI":"10.1177\/2040620720958586","article-title":"High CXCR2 expression predicts poor prognosis in adult patients with acute myeloid leukemia","volume":"11","author":"Tang","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.htct.2023.05.005","article-title":"IL-8 in bone marrow and peripheral blood of patients with B-cell acute lymphoblastic leukemia is associated with high regulatory T cell counts, degree of tumor infiltration and expression of CXCR1 in blasts","volume":"46","author":"Anaya","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Korbecki, J., Kupnicka, P., Barczak, K., Bosiacki, M., Zi\u0119tek, P., Chlubek, D., and Baranowska-Bosiacka, I. (2023). The Role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 Ligands in Molecular Cancer Processes and Clinical Aspects of Acute Myeloid Leukemia (AML). Cancers, 15.","DOI":"10.3390\/cancers15184555"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lu, C., Zhu, J., Chen, X., Hu, Y., Xie, W., Yao, J., and Huang, S. (2020). Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.584766"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10156-011-0321-3","article-title":"Enhancement of interleukin-8-induced chemotactic response and reactive oxygen species production in HL-60 cells expressing CXCR1","volume":"18","author":"Tansho","year":"2012","journal-title":"J. Infect. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1182\/blood-2011-10-386011","article-title":"ALK+ALCLs induce cutaneous, HMGB-1-dependent IL-8\/CXCL8 production by keratinocytes through NF-\u03baB activation","volume":"119","author":"Dejean","year":"2012","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.leukres.2006.06.012","article-title":"Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression","volume":"31","author":"Kline","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_17","first-page":"2060","article-title":"CXCL8 and its cognate receptors CXCR1\/CXCR2 in primary myelofibrosis","volume":"109","author":"Vermeersch","year":"2024","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1080\/10428194.2023.2232492","article-title":"Role of IL8 in myeloid malignancies","volume":"64","author":"Ramachandra","year":"2023","journal-title":"Leuk. Lymphoma."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2003-12-4415","article-title":"IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis","volume":"105","author":"Emadi","year":"2005","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e18552","DOI":"10.1111\/jcmm.18552","article-title":"Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co-expression network analysis","volume":"28","author":"Han","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cao, H., Tadros, V., Hiramoto, B., Leeper, K., Hino, C., Xiao, J., Pham, B., Kim, D.H., Reeves, M.E., and Chen, C.S. (2022). Targeting TKI-Activated NFKB2-MIF\/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051038"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kim, J.H., Lee, S.J., Kang, K.W., Lee, B.H., Park, Y., and Kim, B.S. (2021). CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells. Biochem. Pharmacol., 190.","DOI":"10.1016\/j.bcp.2021.114658"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41419-025-07413-6","article-title":"Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK\/STAT3 pathway","volume":"16","author":"Wang","year":"2025","journal-title":"Cell. Death Dis."},{"key":"ref_24","first-page":"2508","article-title":"CXCL8\/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis","volume":"141","author":"Dunbar","year":"2023","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zou, Z., Chen, S., Wu, Y., and Ji, S. (2024). The USP35-CXCR3 Axis plays an oncogenic role in JeKo-1 mantle cell lymphoma cells. Integr. Biol., 16.","DOI":"10.1093\/intbio\/zyae021"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1111\/cas.15782","article-title":"EBV-positive pyothorax-associated lymphoma expresses CXCL9 and CXCL10 chemokines that attract cytotoxic lymphocytes via CXCR3","volume":"114","author":"Higuchi","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s40425-019-0751-5","article-title":"Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells","volume":"7","author":"Bonanni","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Klement, L., and Drube, J. (2023). The interplay of FLT3 and CXCR4 in acute myeloid leukemia: An ongoing debate. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1258679"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yu, D.H., Chen, C., Liu, X.P., Yao, J., Li, S., and Ruan, X.L. (2021). Dysregulation of miR-138-5p\/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML. Front. Cell. Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.641629"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Roversi, F.M., Bueno, M.L.P., Pericole, F.V., and Saad, S.T.O. (2021). Hematopoietic Cell Kinase (HCK) Is a Player of the Crosstalk Between Hematopoietic Cells and Bone Marrow Niche Through CXCL12\/CXCR4 Axis. Front. Cell. Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.634044"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1172\/JCI120654","article-title":"BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment","volume":"129","author":"Piya","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Macanas-Pirard, P., Quezada, T., Navarrete, L., Broekhuizen, R., Leisewitz, A., Nervi, B., and Ram\u00edrez, P.A. (2017). The CCL2\/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0168888"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ondrisova, L., and Mraz, M. (2020). Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.591577"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/10428194.2021.1910684","article-title":"CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1\/2 and BCL2 inhibition through CNS infiltration","volume":"62","author":"Walker","year":"2021","journal-title":"Leuk. Lymphoma."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood-2015-02-628560","article-title":"CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling","volume":"126","author":"Arnaud","year":"2015","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"35123","DOI":"10.18632\/oncotarget.26212","article-title":"CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton\u2019s tyrosine kinase","volume":"9","author":"Montresor","year":"2018","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"34245","DOI":"10.18632\/oncotarget.5196","article-title":"JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia","volume":"6","author":"Montresor","year":"2015","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"12048","DOI":"10.18632\/oncotarget.3660","article-title":"CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: A role for CCL21","volume":"6","author":"Ganghammer","year":"2015","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.12098","article-title":"Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12\/CXCR4 axis and the NF-kappaB and JNK\/AP-1 pathways","volume":"93","author":"Scupoli","year":"2008","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1182\/blood-2006-03-007294","article-title":"MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration","volume":"108","author":"Samaniego","year":"2006","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1111\/jcmm.13632","article-title":"Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration","volume":"22","author":"Nowak","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1080\/10428194.2018.1455974","article-title":"Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells","volume":"59","author":"Crassini","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1159\/000490142","article-title":"The Critical Role of PTEN\/PI3K\/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia","volume":"47","author":"Chen","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.bbrc.2015.06.020","article-title":"CCR7 is involved in BCR-ABL\/STAP-2-mediated cell growth in hematopoietic Ba\/F3 cells","volume":"463","author":"Kubo","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11899-023-00688-6","article-title":"The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities","volume":"18","author":"Patterson","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bcp.2014.05.007","article-title":"CXCL12\/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562\/ADM cells","volume":"90","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_48","first-page":"139","article-title":"[Molecular mechanisms in the resistance of CML stem cells to tyrosine kinase inhibitors and novel targets for achieving a cure]","volume":"56","author":"Tanaka","year":"2015","journal-title":"Rinsho Ketsueki."},{"key":"ref_49","first-page":"976567","article-title":"Molecularly targeted therapies in multiple myeloma","volume":"2014","author":"Muz","year":"2014","journal-title":"Leuk. Res. Treat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bila, J., Katodritou, E., Guenova, M., Basic-Kinda, S., Coriu, D., Dapcevic, M., Ibricevic-Balic, L., Ivanaj, A., Karanfilski, O., and Zver, S. (2021). Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173940"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: Cells\u2019 journey from bone marrow to beyond","volume":"17","author":"Ullah","year":"2019","journal-title":"J. Bone Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/1744666X.2019.1561283","article-title":"New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions","volume":"15","author":"Schiano","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41375-019-0628-0","article-title":"Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma","volume":"34","author":"Gehringer","year":"2020","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","article-title":"SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma","volume":"130","author":"Balsas","year":"2017","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mc.23515","article-title":"HIF-1\u03b1 mediates CXCR4 transcription to activate the AKT\/mTOR signaling pathway and augment the viability and migration of activated B cell-like diffuse large B-cell lymphoma cells","volume":"62","author":"Jin","year":"2023","journal-title":"Mol. Carcinog."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1080\/10428194.2017.1379077","article-title":"Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma","volume":"59","author":"Xu","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1034\/j.1600-0609.2000.90112.x","article-title":"Binding of stromal derived factor-1alpha (SDF-1alpha) to CXCR4 chemokine receptor in normal human megakaryoblasts but not in platelets induces phosphorylation of mitogen-activated protein kinase p42\/44 (MAPK), ELK-1 transcription factor and serine\/threonine kinase AKT","volume":"64","author":"Majka","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1038\/sj.onc.1207887","article-title":"Jak kinase activity is required for lymphoma invasion and metastasis","volume":"23","author":"Opdam","year":"2004","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/bjh.15670","article-title":"CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression","volume":"185","author":"Leguit","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3904\/kjim.2014.29.6.785","article-title":"Clinical significance of nuclear factor \u03baB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy","volume":"29","author":"Shin","year":"2014","journal-title":"Korean J. Intern. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s11626-018-0293-z","article-title":"CXCR5 overexpression in HL-60 cells enhances chemotaxis toward CXCL13 without anticipated interaction partners or enhanced MAPK signaling","volume":"54","author":"MacDonald","year":"2018","journal-title":"Vitr. Cell. Dev. Biol. Anim."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1078\/0171-9335-00141","article-title":"Retinoic acid-induced blr1 expression requires RARalpha, RXR, and MAPK activation and uses ERK2 but not JNK\/SAPK to accelerate cell differentiation","volume":"80","author":"Battle","year":"2001","journal-title":"Eur. J. Cell. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","article-title":"IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells","volume":"122","author":"Pascutti","year":"2013","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1323155","DOI":"10.1080\/2162402X.2017.1323155","article-title":"The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival","volume":"6","author":"Stache","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","article-title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for interactions with the stromal microenvironment and specific targeting","volume":"113","author":"Kurtova","year":"2009","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ijc.24652","article-title":"Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma","volume":"125","author":"Rehm","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1128\/JVI.78.8.4108-4119.2004","article-title":"Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells","volume":"78","author":"Carter","year":"2004","journal-title":"J. Virol."},{"key":"ref_69","first-page":"209","article-title":"Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13","volume":"20","author":"Zhang","year":"2020","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.leukres.2017.07.003","article-title":"p53 Deletion promotes myeloma cells invasion by upregulating miR19a\/CXCR5","volume":"60","author":"Yue","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"111972","DOI":"10.1016\/j.intimp.2024.111972","article-title":"CXCR6 defines therapeutic subtypes of CD4+ cytotoxic T cell lineage for adoptive cell transfer therapy in pediatric B cell acute lymphoblastic leukemia","volume":"132","author":"Shi","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cbin.11154","article-title":"Soluble CXCL16 promotes TNF-\u03b1-induced apoptosis in DLBCL via the AMAD10-NF-\u03baB regulatory feedback loop","volume":"43","author":"Yang","year":"2019","journal-title":"Cell. Biol. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"174831","DOI":"10.1016\/j.ejphar.2022.174831","article-title":"The contributory roles of the CXCL12\/CXCR4\/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies","volume":"920","author":"Mehrpouri","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Cui, X.Y., Tj\u00f8nnfjord, G.E., Kanse, S.M., Dahm, A.E.A., Iversen, N., Myklebust, C.F., Sun, L., Jiang, Z.X., Ueland, T., and Campbell, J.J. (2021). Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-84695-8"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3727\/096504018X15439207752093","article-title":"miR-101 Represses T-Cell Acute Lymphoblastic Leukemia by Targeting CXCR7\/STAT3 Axis","volume":"27","author":"Yang","year":"2019","journal-title":"Oncol. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.leukres.2018.11.001","article-title":"Chemosensitivity is differentially regulated by the SDF-1\/CXCR4 and SDF-1\/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements","volume":"75","author":"Ando","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13287-017-0765-1","article-title":"CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells","volume":"9","author":"Melo","year":"2018","journal-title":"Stem Cell. Res. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5045\/br.2015.50.4.218","article-title":"Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells","volume":"50","author":"Kim","year":"2015","journal-title":"Blood Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mc.22540","article-title":"Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12\/CXCR7 axis in bone marrow microenvironment","volume":"56","author":"Li","year":"2017","journal-title":"Mol. Carcinog."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/labinvest.2016.28","article-title":"Requirement of CXCL12-CXCR7 signaling for CD20(-) CD138(-) double-negative population in lymphoplasmacytic lymphoma","volume":"96","author":"Wada","year":"2016","journal-title":"Lab. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1476-4598-10-73","article-title":"The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells","volume":"10","author":"Zabel","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bjh.14807","article-title":"CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma","volume":"179","author":"Waldschmidt","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2014-02-558742","article-title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma","volume":"124","author":"Azab","year":"2014","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hellmich, C., Moore, J.A., Bowles, K.M., and Rushworth, S.A. (2020). Bone Marrow Senescence and the Microenvironment of Hematological Malignancies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00230"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Hong, Y., Jeong, S., Park, M.-J., Song, W., and Lee, N. (2024). Application of Pathomic Features for Differentiating Dysplastic Cells in Patients with Myelodysplastic Syndrome. Bioengineering, 11.","DOI":"10.3390\/bioengineering11121230"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Xiao, Y., Yang, K., Huang, Q., Wei, C., Wei, M., Geng, Z., Wu, H., Zhou, T., Yin, X., and Zhou, Y. (2024). Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: Three case reports. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1477697"},{"key":"ref_87","first-page":"92","article-title":"Recurrent cytogenetic abnormalities reveal alterations that promote progression and transformation in myelodysplastic syndrome","volume":"288\u2013289","author":"Alkayyali","year":"2024","journal-title":"Cancer Genet."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Bakkaloglu, I.G., Zemheri, I.E., Kaya, A.H., and Kilicaslan, E. (2024). The Impact of Microenvironment and Dysplasia Types on the Prognosis of Myelodysplastic Syndrome. Diagnostics, 14.","DOI":"10.3390\/diagnostics14232720"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4302515","DOI":"10.1155\/2021\/4302515","article-title":"Increased Circulating CD4+CXCR5+ Cells and IgG4 Levels in Patients with Myelodysplastic Syndrome with Autoimmune Diseases","volume":"2021","author":"Xiao","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"106713","DOI":"10.1016\/j.leukres.2021.106713","article-title":"Combination of dociparstat sodium (DSTAT), a CXCL12\/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS","volume":"110","author":"Huselton","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2022.03.003","article-title":"Epigenetic maintenance strategies after allogeneic stem cell transplantation in acute myeloid leukemia","volume":"109","author":"Yan","year":"2022","journal-title":"Exp. Hematol."},{"key":"ref_92","first-page":"985","article-title":"[The Mechanisms of Piceatannol in Inhibiting the Malignant Biological Characteristics of Acute Myeloid Leukemia Cells]","volume":"31","author":"Liu","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","article-title":"Myeloid malignancies and the microenvironment","volume":"129","author":"Claudia","year":"2017","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1080\/10428194.2018.1434886","article-title":"Targeting the bone marrow microenvironment in acute leukemia","volume":"59","author":"Karantanou","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_95","first-page":"213","article-title":"Abnormal expression and clinical significance of CXC chemokine receptor 1\/2 in acute leukemia","volume":"44","author":"Liu","year":"2023","journal-title":"Acad. J. Chin. Pla Med. Sch."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/s41375-024-02326-3","article-title":"CXCR4 as a therapeutic target in acute myeloid leukemia","volume":"38","author":"Korbecki","year":"2024","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"27917","DOI":"10.1021\/acsnano.4c05079","article-title":"A Dual-Function LipoAraN-E5 Coloaded with N4-Myristyloxycarbonyl-1-\u03b2-d-arabinofuranosylcytosine (AraN) and a CXCR4 Antagonistic Peptide (E5) for Blocking the Dissemination of Acute Myeloid Leukemia","volume":"18","author":"Wang","year":"2024","journal-title":"ACS Nano"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7150\/thno.101215","article-title":"CXCR4-directed endoradiotherapy with [177Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Braitsch","year":"2025","journal-title":"Theranostics"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e17862","DOI":"10.7717\/peerj.17862","article-title":"Prognostic role of chemokine-related genes in acute myeloid leukemia","volume":"12","author":"Hou","year":"2024","journal-title":"PeerJ"},{"key":"ref_100","first-page":"364","article-title":"[The Effects and Regulatory Mechanism of Targeting CXC Chemokine Receptor 1\/2 Combined with Ara-C on the Malignant Biological Behaviors of U937 Cells of Acute Myeloid Leu-kemia]","volume":"31","author":"Liu","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Verachi, P., Gobbo, F., Martelli, F., Martinelli, A., Sarli, G., Dunbar, A., Levine, R.L., Hoffman, R., Massucci, M.T., and Brandolini, L. (2022). The CXCR1\/CXCR2 inhibitor Reparixin alters the development of myelofibrosis in the Gata1low mice. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.853484"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"106442","DOI":"10.1016\/j.leukres.2020.106442","article-title":"Plerixafor in combination with chemotherapy and\/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies","volume":"97","author":"Maganti","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_103","unstructured":"Hematology Oncology Committee, Chinese Anti-Cancer Association, and Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association (2024). [Chinese guideline for diagnosis and treatment of adult acute lymphoblastic leu-kemia (2024)]. Zhonghua Xue Ye Xue Za Zhi, 45, 417\u2013429. (In Chinese)."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2021011557","article-title":"The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13","volume":"138","author":"Zanetti","year":"2021","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5601396","DOI":"10.1155\/2019\/5601396","article-title":"Notch\/CXCR4 Partnership in Acute Lymphoblastic Leukemia Progression","volume":"2019","author":"Tsaouli","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e13076","DOI":"10.1111\/cpr.13076","article-title":"Role of CXCR4 in the progression and therapy of acute leukaemia","volume":"54","author":"Su","year":"2021","journal-title":"Cell Prolif."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Pohl, J., Litz, A., El Ayoubi, O., Rodr\u00edguez-Alfonso, A., St\u00e4ndker, L., Harms, M., M\u00fcnch, J., Jumaa, H., and Datta, M. (2024). An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR\u2013ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158306"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1038\/s41467-024-48818-9","article-title":"Glucocorticoids paradoxically promote steroid resistance in B cell acute lympho-blastic leukemia through CXCR4\/PLC signaling","volume":"15","author":"Hami","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjh.18607","article-title":"CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance","volume":"201","author":"Jonart","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1002\/1878-0261.13306","article-title":"Growth arrest-specific protein 2 (GAS2) interacts with CXCR4 to promote T-cell leukemo-genesis partially via c-MYC","volume":"16","author":"Ma","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.12688\/f1000research.125877.2","article-title":"General anaesthetics reduce acute lymphoblastic leukaemia malignancies in vitro and in vivovia CXCR4 and osteopontin mediated mechanisms","volume":"11","author":"Jiang","year":"2024","journal-title":"F1000Research"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Rocco, S., Maglione, A., Schiavo, V., Ferrando, A., Fava, C., Cilloni, D., Pergolizzi, B., and Panuzzo, C. (2025). Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020392"},{"key":"ref_114","first-page":"65","article-title":"Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)","volume":"18","author":"Scalzulli","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e22091","DOI":"10.1016\/j.heliyon.2023.e22091","article-title":"CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K\/Akt\/mTOR and dipeptidylpeptidase \u2163 (CD26)","volume":"9","author":"Kim","year":"2023","journal-title":"Heliyon"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"109386","DOI":"10.1016\/j.celrep.2021.109386","article-title":"TNF-\u03b1-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling","volume":"36","author":"Agarwal","year":"2021","journal-title":"Cell Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1111\/jcmm.14910","article-title":"Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance","volume":"24","author":"Herrmann","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_119","unstructured":"Hematology Committee of Chinese Medical Association, Hematological Oncology Committee of China Anti-Cancer Associa-tion, and Chinese Working Group for Chronic Lymphocytic Leukemia (2018). [The guidelines for diagnosis and treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma in China (2018 edition)]. Zhonghua Xue Ye Xue Za Zhi, 39, 353\u2013358. (In Chinese)."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jamaoncol.2015.0779","article-title":"Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era","volume":"1","author":"Nabhan","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"300060520918087","DOI":"10.1177\/0300060520918087","article-title":"CD56-positive diffuse large B-cell lymphoma\/leukemia with BCL6\/MYC double-hit and multiple gene mutations: An indicator of poor prognosis?","volume":"48","author":"Liu","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Chen, X., Wang, J., Liu, Y., Lin, S., Shen, J., Yin, Y., and Wang, Y. (2024). Primary intestinal diffuse large B-cell lymphoma: Novel insights and clinical perception. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1404298"},{"key":"ref_123","first-page":"e75161","article-title":"Lymphomas with Primary Gastrointestinal Presentation: A Retrospective Study Covering a Five-Year Period at a Quaternary Care Center in Southern India","volume":"16","author":"George","year":"2024","journal-title":"Cureus"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1007\/s11033-023-08626-8","article-title":"Gene expression study of host-human T-cell leukaemia virus type 1 (HTLV-1) interactions: Adult T-cell leukaemia\/lymphoma (ATLL)","volume":"50","author":"Rahimzada","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Antonello, P., Pizzagalli, D.U., Foglierini, M., Melgrati, S., Radice, E., Thelen, S., and Thelen, M. (2023). ACKR3 promotes CXCL12\/CXCR4-mediated cell-to-cell-induced lymphoma migration through LTB4 production. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1067885"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s11307-023-01830-9","article-title":"Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging","volume":"25","author":"Kosmala","year":"2023","journal-title":"Mol. Imaging Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cellsig.2017.08.002","article-title":"The role of G protein-coupled receptors in lymphoid malignancies","volume":"39","author":"Nugent","year":"2017","journal-title":"Cell. Signal."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstr\u00f6m macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1038\/s41375-021-01376-1","article-title":"CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness","volume":"35","author":"Lewis","year":"2021","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Pansy, K., Feichtinger, J., Ehall, B., Uhl, B., Sedej, M., Roula, D., Pursche, B., Wolf, A., Zoidl, M., and Steinbauer, E. (2019). The CXCR4\u2013CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro. Int. J. Mol. Sci., 20.","DOI":"10.20944\/preprints201907.0352.v1"},{"key":"ref_131","first-page":"46","article-title":"Analysis of the Status of Traditional Chinese Medicine in the Diagnosis and Treatment of Multiple Myeloma","volume":"4","author":"Liu","year":"2022","journal-title":"J. Oncol. Chin. Med."},{"key":"ref_132","first-page":"794","article-title":"[Experimental Study on the Mechanism of Mangiferin Inhibiting Malignant Biological Characteristics of Multiple Myeloma and Exerting Anticancer Effect]","volume":"31","author":"Liu","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13046-025-03382-y","article-title":"The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse","volume":"44","author":"Muylaert","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e41707","DOI":"10.1097\/MD.0000000000041707","article-title":"Comprehensive bioinformatics analysis reveals key hub genes linked to prognosis in multiple myeloma with drug resistance","volume":"104","author":"Chen","year":"2025","journal-title":"Medicine"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Sawasdee, N., Thepmalee, C., Junking, M., Okada, S., Panya, A., and Yenchitsomanus, P.-T. (2025). Enhancing T cell cytotoxicity in multiple myeloma with bispecific \u03b1PD-L1 \u00d7 \u03b1CD3 T cell engager-armed T cells and low-dose bortezomib therapy. Biomed. Pharmacother., 184.","DOI":"10.1016\/j.biopha.2025.117878"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Ito, S., Sato, T., and Maeta, T. (2021). Role and Therapeutic Targeting of SDF-1\u03b1\/CXCR4 Axis in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13081793"},{"key":"ref_137","first-page":"1962","article-title":"[Correlation between Expression of CXCL12, CXCR4, VEGF, MVD and Prognosis in Patients with Multiple Myeloma]","volume":"28","author":"Zhang","year":"2020","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"E341","DOI":"10.1016\/j.clml.2020.02.016","article-title":"Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma","volume":"20","author":"Mouhieddine","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"19702","DOI":"10.1002\/jcp.28570","article-title":"Blockade of SDF-1\/CXCR4 reduces adhesion-mediated chemoresistance of multiple mye-loma cells via interacting with interleukin-6","volume":"234","author":"Liu","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_140","first-page":"1141","article-title":"Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis","volume":"18","author":"Yang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/ajh.25627","article-title":"Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma","volume":"94","author":"Ghobrial","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/sj.leu.2403732","article-title":"Significance of chemokine receptor expression in aggressive NK cell leukemia","volume":"19","author":"Makishima","year":"2005","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bcmd.2008.08.002","article-title":"Chemokine receptor repertoire reflects mature T-cell lymphoproliferative disorder clinical presentation","volume":"42","author":"Moura","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2141.2007.06686.x","article-title":"Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity","volume":"138","author":"Trentin","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.exphem.2023.02.003","article-title":"Inhibition of CXCR1\/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis","volume":"121","author":"Arciprete","year":"2023","journal-title":"Exp. Hematol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Levidou, G., Sachanas, S., Pangalis, G.A., Kalpadakis, C., Yiakoumis, X., Moschogiannis, M., Sepsa, A., Lakiotaki, E., Milionis, V., and Kyrtsonis, M.C. (2014). Immunohistochemical analysis of IL-6, IL-8\/CXCR2 axis, \u2009Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: Correlation between microvascular characteristics and prognostic significance. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/251479"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1523-1747.1998.00263.x","article-title":"Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas","volume":"111","author":"Tensen","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"7084268","DOI":"10.1155\/2020\/7084268","article-title":"High CXCR3 on Leukemic Cells Distinguishes IgHVmut from IgHVunmut in Chronic Lymphocytic Leukemia: Evidence from CD5high and CD5low Clones","volume":"2020","author":"Manukyan","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cancergen.2017.09.002","article-title":"Differences between chronic lymphocytic leukaemia and small lymphocytic lymphoma cells by proteomic profiling and SNP microarray analysis","volume":"218\u2013219","author":"Tooze","year":"2017","journal-title":"Cancer Genet."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4132\/jptm.2024.01.04","article-title":"Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified","volume":"58","author":"Han","year":"2024","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4556586","DOI":"10.1155\/2023\/4556586","article-title":"Coexpression of PD-L1\/PD-1 with CXCR3\/CD36 and IL-19 Increase in Extranodal Lymphoma","volume":"2023","author":"Saber","year":"2023","journal-title":"J. Immunol. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s10147-022-02285-8","article-title":"Reciprocal expression of the immune response genes CXCR3 and IFI44L as module hubs are associated with patient survivals in primary central nervous system lymphoma","volume":"28","author":"Takashima","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.canlet.2003.10.036","article-title":"CXCR3-binding chemokines in multiple myeloma","volume":"207","author":"Pellegrino","year":"2004","journal-title":"Cancer Lett."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e15948","DOI":"10.1097\/MD.0000000000015948","article-title":"Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia","volume":"98","author":"Cao","year":"2019","journal-title":"Medicine"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7754\/Clin.Lab.2019.190725","article-title":"Association of CXCR4 Expression and Clinical Outcome in Different Subsets of De Novo Acute Myeloid Leukemia Patients","volume":"66","author":"Rady","year":"2020","journal-title":"Clin. Lab."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2141.2001.03164.x","article-title":"High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia","volume":"115","author":"Crazzolara","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2013.10.016","article-title":"High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia","volume":"38","author":"Ko","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1002\/cam4.2535","article-title":"Prognostic significance of CXCR4 expression in acute myeloid leukemia","volume":"8","author":"Du","year":"2019","journal-title":"Cancer Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55133\/eji.280312","article-title":"CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients","volume":"28","author":"Aly","year":"2021","journal-title":"Egypt. J. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.18632\/oncotarget.3343","article-title":"Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.amjms.2019.01.008","article-title":"CXCR4 and CCR7 Expression in Primary Nodal Diffuse Large B-Cell Lymphoma-A Clinical and Immunohistochemical Study","volume":"357","author":"Du","year":"2019","journal-title":"Am. J. Med. Sci."},{"key":"ref_162","first-page":"3276925","article-title":"Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics","volume":"2022","author":"Zhang","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-21-3284","article-title":"Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands","volume":"28","author":"Kwon","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Mazur, G., Butrym, A., Kryczek, I., Dlubek, D., Jaskula, E., Lange, A., Kuliczkowski, K., and Jelen, M. (2014). Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factor. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098194"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.leukres.2013.06.002","article-title":"CXCR4 is a good survival prognostic indicator in multiple myeloma patients","volume":"37","author":"Bao","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17474086.2022.2113772","article-title":"Reduced CXCR4 expression in associated with extramedullary and predicts poor survival in newly diagnosed multiple myeloma","volume":"15","author":"Chen","year":"2022","journal-title":"Expert. Rev. Hematol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bcmd.2007.01.003","article-title":"The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia","volume":"38","author":"Rosti","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12032-012-0341-6","article-title":"Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome","volume":"30","author":"Zhang","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e70005","DOI":"10.1002\/kjm2.70005","article-title":"Expression and Clinical Significance of CXCR5 and LAG-3 on Peripheral Blood CD8+ T Cells in Patients with Diffuse Large B-Cell Lymphoma","volume":"17","author":"Guo","year":"2025","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00262-013-1452-4","article-title":"CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis","volume":"62","author":"Charbonneau","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_171","first-page":"1300","article-title":"[Expression of CXCR7 in Acute Monocytic Leukemia and Its Effects on THP-1 Cell Functions]","volume":"25","author":"Hu","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Moreno, M.J., Gallardo, A., Novelli, S., Mozos, A., Arag\u00f3, M., Pav\u00f3n, M.\u00c1., C\u00e9spedes, M.V., Pallar\u00e8s, V., Falg\u00e0s, A., and Alcoceba, M. (2018). CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198789"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"de Vasconcellos, J.F., Laranjeira, A.B., Leal, P.C., Bhasin, M.K., Zenatti, P.P., Nunes, R.J., Yunes, R.A., Nowill, A.E., Libermann, T.A., and Zerbini, L.F. (2015). SB225002 Induces Cell Death and Cell Cycle Arrest in Acute Lymphoblastic Leukemia Cells through the Activation of GLIPR1. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134783"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e26414","DOI":"10.1002\/pbc.26414","article-title":"A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators\u2019 Consortium study (POE 10-03)","volume":"64","author":"Cooper","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/10428194.2021.1872068","article-title":"A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes","volume":"62","author":"Huselton","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1080\/10428194.2019.1643463","article-title":"A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia","volume":"60","author":"Andritsos","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.bbmt.2019.01.014","article-title":"Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability","volume":"25","author":"Michelis","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3324\/haematol.2017.183418","article-title":"Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia","volume":"103","author":"Roboz","year":"2018","journal-title":"Haematologica"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.18632\/oncotarget.2407","article-title":"Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: Efficacy and potential mechanisms of resistance to CXCR4 inhibition","volume":"5","author":"Sison","year":"2014","journal-title":"Oncotarget"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.exphem.2012.11.004","article-title":"Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice","volume":"41","author":"Welschinger","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood-2011-05-355396","article-title":"Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML","volume":"120","author":"Agarwal","year":"2012","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1080\/10428190903150847","article-title":"Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib","volume":"50","author":"Dillmann","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3324\/haematol.2011.052779","article-title":"AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: Pre-clinical evidence for its association with chronic lymphocytic leukemia treatments","volume":"97","author":"Stamatopoulos","year":"2012","journal-title":"Haematologica"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1007\/s00277-024-06103-1","article-title":"Plerixafor in association with R-DHAP and G-CSF to mobilize a large number of CD34\u2009+\u2009 cells in patients with relapsed-refractory diffuse large B-cell lymphomas","volume":"103","author":"Gaudio","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ajpath.2023.04.013","article-title":"AMD3100-Mediated CXCR4 Inhibition Impairs Development of Primary Lymphoma of the Central Nervous System","volume":"193","author":"Siebert","year":"2023","journal-title":"Am. J. Pathol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.3390\/cancers15194783","article-title":"Prospective Comparative Study of Etoposide plus G-CSF versus G-CSF Alone, Followed by Risk-Adapted Plerixafor for Peripheral Blood Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma: CAtholic REsearch Network for Multiple Myeloma Study (CAREMM-2001)","volume":"15","author":"Park","year":"2023","journal-title":"Cancers"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s44228-023-00030-0","article-title":"Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)","volume":"5","author":"Malard","year":"2023","journal-title":"Clin. Hematol. Int."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"103618","DOI":"10.1016\/j.transci.2022.103618","article-title":"The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients","volume":"62","author":"He","year":"2023","journal-title":"Transfus. Apher. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/hon.3055","article-title":"Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients","volume":"41","author":"Maechler","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clml.2021.07.030","article-title":"Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient","volume":"22","author":"Prakash","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/bloodadvances.2017013391","article-title":"Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia","volume":"2","author":"Kovacsovics","year":"2018","journal-title":"Blood Adv."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3324\/haematol.2018.205930","article-title":"Olaptesed pegol (NOX-A12) with bendamustine and rituximab: A phase IIa study in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"104","author":"Steurer","year":"2019","journal-title":"Haematologica"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1182\/bloodadvances.2023010407","article-title":"Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor","volume":"7","author":"Crees","year":"2023","journal-title":"Blood Adv."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12964-024-01544-7","article-title":"Research progress of the chemokine\/chemokine receptor axes in the oncobiology of multiple myeloma (MM)","volume":"22","author":"Du","year":"2024","journal-title":"Cell. Commun. Signal."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1177\/10781552241247472","article-title":"A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection","volume":"30","author":"Dietz","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1078-0432.CCR-19-0647","article-title":"A Phase Ib\/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma","volume":"26","author":"Ghobrial","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.18632\/oncotarget.6465","article-title":"Ulocuplumab (BMS-936564 \/ MDX1338): A fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/1078-0432.CCR-12-2333","article-title":"BMS-936564\/MDX-1338: A fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies","volume":"19","author":"Kuhne","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/5\/716\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:32:04Z","timestamp":1760031124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/5\/716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":198,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["biom15050716"],"URL":"https:\/\/doi.org\/10.3390\/biom15050716","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}